Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06468527
Other study ID # HIT-CF-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 3, 2024
Est. completion date June 1, 2025

Study information

Verified date June 2024
Source UMC Utrecht
Contact C.K. van der Ent
Phone +31887553201
Email k.vanderent@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR modulators have focused on patients carrying the F508del CFTR mutation, which is present in approximately 80% of CF patients, or gating mutations which are present in 5% of CF patients (gating mutations result in a reduced opening of the CFTR-channel at the cell surface which limits the flow of chloride ions through the CFTR channel). Although CF is a monogenetic disease, the 15% remaining patients represent more than 2000 different rare and mostly uncharacterized CFTR mutations. Multiple pharma companies have one or more CF drugs in their developmental pipeline. However, it is not known which patients may respond to the drugs in the pipeline. It is hypothesized that by using individual patient's intestinal organoids to screen for drug response, a subset of patients with rare CFTR mutations can be identified who will clinically respond to drugs in the developmental pipeline. The Human Individualized Therapy of CF (HIT-CF) project has been designed to further evaluate this hypothesis. The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 755021. The core of the project consists of a two-step approach to identify patients outside the existing drug label who may also benefit from CFTR-modulator treatment. In the first step of the project (HIT-CF Organoid Study, NTR7520), novel CFTR modulators and their combinations were tested on organoids from over 500 European and Israeli CF patients with rare CFTR mutations to identify patients who are predicted to clinically benefit from these treatments. The second step will evaluate the predicted clinical effect of the CFTR modulators in subjects identified by their organoid response to investigational products. CFTR modulators from the HIT-CF participating pharmaceutical company, FAIR Therapeutics, will be evaluated in the CHOICES clinical study described in this protocol. Data from this clinical study will be compared with the HIT-CF Organoid Study results to validate the organoid model.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date June 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: A subject must meet ALL the following criteria in order to participate: 1. Male or female subjects who completed the HIT-CF Organoid Study and are 18 years of age or older on the date of informed consent 2. Confirmed diagnosis of CF as follows: - Sweat chloride value of =60 mmol/L based on quantitative pilocarpine iontophoresis (at screening) OR 2 CF-causing mutations AND - chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities 3. Clinically stable CF disease in the opinion of the investigator with no significant changes in health status within 28 days prior to Day 1 4. Forced expiratory volume in one second (FEV1) =40% of predicted to =90% of predicted at the Screening Visit, based on the Global Lung Function Initiative (GLI) -2012 multi-ethnic all-age reference equations 5. Body mass index (BMI) =16 kg/m2 and =30 kg/m2 6. Non-smoker and non-tobacco user (including all inhalational nicotine delivery systems) for a minimum of 30 days prior to screening, and subject agrees not to smoke or use tobacco for the duration of the study 7. Subjects of childbearing potential must meet contraception requirements (Section 13.3.1) 8. Willing to remain on a stable medication regimen for CF from 28 days before Day 1 through the last study visit 9. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, and other study procedures 10. Selected by an unblinded coordinating team based on organoid response or random selection 11. Subject will sign and date an informed consent form (ICF Exclusion Criteria: A subject who meets ANY of the following criteria will be excluded from participation: 1. Subject has at least one of the following CFTR-mutations: F508del, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H, A455E, 3849+10kbC>T OR A combination of any two of the following mutations: any nonsense mutation, 1717-1G>A, 621+1G>T, 3120+1G>A, 1898+1G->A, CFTRdele2,3, and 2183AA->G 2. History or current evidence of any clinically significant cardiac (eg, heart failure, left ventricular hypertrophy, myocardial infarction, and arrhythmia), endocrinologic, hematologic, hepatobiliary (eg, clinically significant cirrhosis with or without portal hypertension, hepatitis B or hepatitis C), immunologic, metabolic, urologic, pulmonary (besides CF), neurologic (eg, subarachnoid haemorrhage, intracranial haemorrhage, cerebrovascular accident, intracranial trauma, and autonomic neuropathy), dermatologic, psychiatric, renal, or other major disease, that is unstable or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator 3. Clinically significant screening results that would exclude subject from the study (eg, medical history, physical examination, ECG, vital sign, pulse oximetry, and laboratory profiles) or any conditions that, would make the subject unsuitable for enrolment or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator. The medical monitor must be contacted for review of any subjects with screening results or conditions that may make them unsuitable for enrolment or could interfere with participation in or completion of the study. 4. Prolonged QTcF >450 msec at screening 5. Abnormal liver function as defined by AST, ALT, gamma-glutamyl transferase (GGT), or alkaline phosphatase =3 times or total bilirubin =2 times upper limit of the normal range 6. Haemoglobin <10 g/dL 7. Platelet count <150,000 cells/mm3 8. Abnormal renal function at screening defined as creatinine clearance <60 mL/min using the Modified Diet in Renal Disease (MDRD) 9. Hospitalisation, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness (in the opinion of the investigator) requiring an increase or addition of medication, such as antibiotics or corticosteroids, within 28 days of Day 1 10. Lung infection with organisms associated with a more rapid decline in pulmonary status (eg, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus). Subjects who have a current or past history of a positive culture must be reviewed with the medical monitor to confirm clinical stability. 11. Subject is currently taking or has taken a CFTR modulator within 28 days prior to Day 1 12. Participation in another clinical trial or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to screening. The duration of the elapsed time may be longer if required by local regulations 13. History of cancer (excluding cervical carcinoma in situ and non-melanoma skin cancer with curative therapy for at least 5 years prior to screening) 14. History of organ or hematologic transplantation 15. History or current evidence of alcohol or drug abuse or dependence within 12 months of screening, in the opinion of the investigator 16. Initiation of any new chronic therapy (eg, ibuprofen, hypertonic saline, azithromycin, dornase alfa, aztreonam for inhalation solution, and tobramycin) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to Day 1 17. Known or suspected hypersensitivity or idiosyncratic reaction to the study drugs or any components thereof 18. Pregnant or nursing women 19. Special or vulnerable status (e.g. institutionalized, or person related to or an employee of the sponsor, FAIR Therapeutics, or investigator)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Diponecaftor
Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains: DIR 300 mg/day POS 600 mg/day NES 10 mg/day
Placebo
Placebo once daily for 8 weeks. Oral administration.

Locations

Country Name City State
Belgium UZ Leuven Leuven Vlaams-Brabant
France CHU de Nice Nice
France Hôpital Larrey CHU Toulouse Toulouse
Germany Charité Universitätsmedizin Berlin Berlin
Germany Medizinische Hochschule Hannover Hanover
Italy Instituto Giannina Gaslini Genova
Italy Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan
Italy Ospedale Pediatrico Bambino Gesù Rome
Italy Azienda Ospedaliera Universitaria Integrata Verona
Netherlands UMC Utrecht Utrecht
Portugal Hospital de Santa Maria Lisboa
Spain Hospital Vall d'Hebron Barcelona
Sweden Sahlgrenska University Hospital, Gothenburg CF center Gothenburg
United Kingdom University Hospitals Birmingham NHS Foundation Trust Birmingham
United Kingdom Royal Brompton Hospital London
United Kingdom University Hospital Southampton Southampton

Sponsors (2)

Lead Sponsor Collaborator
Kors van der Ent European Union

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Netherlands,  Portugal,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean percent predicted forced expiratory volume in 1 second (ppFEV1) The primary endpoint in both groups is the mean percent predicted forced expiratory volume in 1 second (ppFEV1) of measurements taken after 4, 6 and 8 weeks of treatment. Period baseline values will be corrected for in the analysis. Measurements taken at 4, 6 and 8 weeks of treatment
Secondary Sweat chloride The average of the sweat chloride measurements taken after 4, 6 and 8 weeks of treatment. Measurements taken at 4, 6 and 8 weeks of treatment
Secondary Body weight The average of the body weight measurements taken after 4, 6 and 8 weeks of treatment Measurements taken at 4, 6 and 8 weeks of treatment
Secondary Cystic Fibrosis Questionnaire Revised (CFQ R) respiratory domain The average of the Cystic Fibrosis Questionnaire Revised (CFQ R) respiratory domain measurements taken after 4, 6 and 8 weeks of treatment. Scores range from 0 to 100, with higher scores indicating better health. Measurements taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Safety and tolerability assessments based on treatment-emergent Adverse Events (AEs) Through study completion, an average of 30 weeks
Secondary Safety and tolerability assessments Safety and tolerability assessments based on treatment-emergent Serious Adverse events (SAEs) Through study completion, an average of 30 weeks
Secondary Safety and tolerability assessments Platelet count Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Liver function (total bilirubin) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Liver function (alkaline phosphatase (ALP)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Liver function (alanine transaminase (ALT)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Liver function (gamma-glutamyl transferase (GGT)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Anemia (Haemoglobin (Hb)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Anemia (Haematocrit) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Anemia (Red blood cell count) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments White blood cell count (including differential) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Glucose measured in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Sodium in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Cholesterol in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Total protein in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Potassium in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Chloride in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Bicarbonate in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Lactate dehydrogenase in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Albumine in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Calcium in blood Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments GFR MDRD (equation based on sex, ethnicity, age, blood urea nitrogen (BUN), creatinine) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Ketonuria (ketones measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Proteinuria (protein measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Hematuria (blood measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Glucosuria (glucose measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments pH of urine (pH measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Specific gravitiy of urine (measured by urine dipstick) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Coagulation (activated partial thromboplastin time (aPTT)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Coagulation (prothrombin time international normalized ratio (PT-INR)) Measurement taken at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments ECG QT Interval Measurement taken at 4 weeks of treatment
Secondary Safety and tolerability assessments Systolic and diastolic blood pressure Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Heart rate Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Respiratory rate Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Body temperature Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
Secondary Safety and tolerability assessments Pulse oximetry measurements Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A